Epigenetic Silencing of RFX7 Defines a Transcriptional Axis Linking Lactate Metabolism to Immune Checkpoint Therapy in Glioblastoma
Advanced Science · 2026
DOI: 10.1002/advs.202523792 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Liying Han und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Epigenesis, Genetic, Lactic Acid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Fund of Tangdu Hospital.
Abstract (Originalsprache)
Glioblastoma (GBM) is a highly aggressive brain tumor characterized by rapid proliferation, diffuse invasion, and robust immunosuppression. Although excessive aerobic glycolysis and lactate accumulation are known to contribute to an immunosuppressive microenvironment, the upstream transcriptional mechanisms connecting metabolic reprogramming and immunotherapy resistance in GBM remain unclear. By integrating transcriptomic profiling, chromatin immunoprecipitation sequencing, and metabolic analysis with gene perturbation experiments, we identified a regulatory axis comprising RFX7 and its downstream target PIK3IP1. In GBM tissues, RFX7 expression was reduced due to promoter hypermethylation. Restoration of RFX7 enhanced PIK3IP1 expression, suppressed PI3K/AKT activation, and inhibited malignant progression in GBM. Loss of PIK3IP1 increased lactate production and histone H4K12 lactylation (H4K12la), coinciding with upregulation of PD‐L1 and CSF1 and enhanced tumor immunosuppressive features. Pharmacological inhibition of lactate production with Stiripentol reduced H4K12la level, intracranial tumor growth, and immunosuppressive cell infiltration, while improving survival and response to immune checkpoint based therapy in experimental models. These findings identify an upstream transcriptional pathway linking lactate metabolism, histone lactylation, and immune suppression in GBM. Targeting the RFX7‐PIK3IP1 axis provides a mechanistic rationale for metabolic‐immune modulation in therapy, addressing an aspect that has remained insufficiently understood in GBM immune resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
- Department of Neurosurgery, Air Force Hospital of Eastern Theater, Nanjing, Jiangsu, China.
ORCID-Profile: Liying Han, Yan Qu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Fund of Tangdu Hospital
Zitieren
APA
Han, L., Zhou, J., Zhu, G., Chen, F., Li, L., Cui, W., Sun, F., Feng, T., Zhang, Y., Wang, Q., Ma, S., Guo, C., Zhang, Z., Wang, K., Wang, J., Wang, L., Li, W., Yuan, C., Liu, H., …, & Qu, Y. (2026). Epigenetic Silencing of RFX7 Defines a Transcriptional Axis Linking Lactate Metabolism to Immune Checkpoint Therapy in Glioblastoma. Advanced Science. https://doi.org/10.1002/advs.202523792
Vancouver
Han L, Zhou J, Zhu G, Chen F, Li L, Cui W, et al. Epigenetic Silencing of RFX7 Defines a Transcriptional Axis Linking Lactate Metabolism to Immune Checkpoint Therapy in Glioblastoma. Advanced Science. 2026. doi:10.1002/advs.202523792
BibTeX
@article{Han2026,
author = {Han, Liying and Zhou, Jinpeng and Zhu, Gang and Chen, Fan and Li, Leiyang and Cui, Wenxing and Sun, Fang and Feng, Tian and Zhang, Yue and Wang, Qiang and Ma, Shuoyao and Guo, Chengxuan and Zhang, Ziwen and Wang, Kai and Wang, Jiahui and Wang, Liangbo and Li, Wencong and Yuan, Chenyi and Liu, Haixiao and Wang, Liang and Qu, Yan},
title = {Epigenetic Silencing of RFX7 Defines a Transcriptional Axis Linking Lactate Metabolism to Immune Checkpoint Therapy in Glioblastoma},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202523792}
}
EUVIMED